✦ LIBER ✦

Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of patients with advanced head and neck cancer

✍ Scribed by Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. Woods

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 435 KB
Volume: 47
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19810115)47:2<240::aid-cncr2820470206>3.0.co;2-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chemotherapy for advanced head and neck

Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen

✍ Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB 👁 1 views

Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m2, day 1; cyclophosphamide, 400 mg/m2, day 3; and cis-diamminedichloroplatinum, 20 mg/m2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0112 squamous cell carcinomas; 112 ad

Chemotherapy of advanced head and neck c

Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective outpatient schedule

✍ Steven E. Vogl; Barry H. Kaplan 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB 👁 1 views

Adriamycin, BCNU plus cyclophosphamide (

Adriamycin, BCNU plus cyclophosphamide (ABC) in advanced carcinoma of the head and neck

✍ Cary A. Presant; Gary Ratkin; Carol Klahr; Carol Brown 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB 👁 1 views

Mitomycin-C, methotrexate, bleomycin and

Mitomycin-C, methotrexate, bleomycin and cis-diamminedichloroplatinum II in the chemotherapy of advanced squamous cancer of the head and neck

✍ Steven E. Vogl; Harvey Lerner; Barry H. Kaplan; Fernando Camacho; James Cinberg; 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 2 views

Cis-diamminedichloroplatinum (II) admini

Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer

✍ Edward T. Creagan; Judith R. O'Fallon; John E. Woods; James N. Ingle; Allan J. S 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 364 KB 👁 1 views

A regression rate of 12% (4/33) among patients with advanced upper aerodigestive carcinomas who received an intravenous regimen of cis-diamminedichloroplatinum, 90 mg/mz/24 hours each three weeks was achieved. The response rate was 13% (3/23) among patients with typical squamous cell carcinoma. Most

A phase II study of piritrexim in patien

A phase II study of piritrexim in patients with advanced squamous head and neck cancer

✍ Wu-Ching Uen; Andrew T. Huang; Robert Mennel; Stephen E. Jones; Monica B. Spauld 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 2 views

Piritrexim (PTX) is a newly developed lipid-soluble folate antagonist that crosses the cell membrane by a simple, rapid, carrier-independent diffusion process. A Phase II study was conducted to evaluate the activity of PTX in 34 patients with previously chemotherapy-naive squamous cell cancer of the